After attracting multiple Chinese pharma partners, XtalPi grabs another $400M to refine AI for drug discovery
Building the kind of artificial intelligence infrastructure required to make a dent in drug discovery takes real money — money that investors have been happy to lavish. Big players, or emerging ones flush with cash, are now popping up on the map in every direction you look: Exscientia in Oxford, UK; Daphne Koller’s insitro in San Francisco; Recursion in Utah; Deep Genomics in Toronto; and Insilico in Hong Kong.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.